Steven M. Johnson, Ph.D.

Biochemistry and Molecular Biology Indiana Univ. School of Medicine 
Chemical Biology / Medicinal Chemistry
"Steven Johnson"
Mean distance: 8.73


Sign in to add mentor
Jeffery W. Kelly grad student 2006 Scripps Institute
 (The design, synthesis, and biophysical evaluation of small molecules to study and selectively inhibit transthyretin amyloidosis.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Connelly S, Mortenson DE, Choi S, et al. (2017) Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors. Bioorganic & Medicinal Chemistry Letters
Abdeen S, Salim N, Mammadova N, et al. (2016) GroEL/ES inhibitors as potential antibiotics. Bioorganic & Medicinal Chemistry Letters. 26: 3127-34
Lee AJ, Wang G, Jiang X, et al. (2015) Canonical Organization of Layer 1 Neuron-Led Cortical Inhibitory and Disinhibitory Interneuronal Circuits. Cerebral Cortex (New York, N.Y. : 1991). 25: 2114-26
Johnson SM, Sharif O, Mak PA, et al. (2014) A biochemical screen for GroEL/GroES inhibitors. Bioorganic & Medicinal Chemistry Letters. 24: 786-9
Johnson SM, Murphy RC, Geiger JA, et al. (2012) Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity. Journal of Medicinal Chemistry. 55: 2416-26
Johnson SM, Connelly S, Fearns C, et al. (2012) The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. Journal of Molecular Biology. 421: 185-203
Connelly S, Choi S, Johnson SM, et al. (2010) Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Current Opinion in Structural Biology. 20: 54-62
Choi S, Reixach N, Connelly S, et al. (2010) A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity. Journal of the American Chemical Society. 132: 1359-70
Johnson SM, Wiseman L, Paulsson JF, et al. (2010) Understanding and Ameliorating the TTR Amyloidoses Protein Misfolding Diseases: Current and Emerging Principles and Therapies. 967-1003
Johnson SM, Connelly S, Wilson IA, et al. (2009) Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. Journal of Medicinal Chemistry. 52: 1115-25
See more...